Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Xintong LiKathleen M AndersenHsien-Yen ChangJeffrey R CurtisG Caleb AlexanderPublished in: Annals of the rheumatic diseases (2019)
Relative to TNF and IL-17, IL-12/23 inhibitors were associated with a reduced risk of serious infection in biologic-naïve patients with PsO or PsA. In biologic-experienced individuals, there was no difference in infection risk across TNF, IL-17 or IL-12/23 inhibitors.